Innovative collaboration focused on developing the first comprehensive Quality of Life dataset for glioblastoma patients [EIN PressWire June 21, 2022] xCures, Inc., is proud to announce their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients. The alliance… Read more »
Category: Uncategorized
Prognos Health and xCures Partner to enable Access to Real World Oncology Datasets
The new collaboration focuses on improving outcomes by continuous learning from every patient’s journey across diverse datasets CHICAGO, IL, UNITED STATES, June 3, 2022 /EINPresswire/ Today, at the annual meeting of the American Society of Clinical Oncology (ASCO), Prognos Health and xCures announced a collaboration to enable real-world data access… Read more »
xCures joins C-Path’s Cure Drug Repurposing Collaboratory to Deliver AI-enabled Data Abstraction of Health Records
Members of CDRC will be able to utilize xCures’ technology to quickly abstract and structure clinical data to support drug repurposing studies in rare cancer. xCures today announced has joined the Critical Path Institute’s (C-Path) Cure Drug Repurposing Collaboratory (CDRC). CRDC is operated by C-Path as a public-private partnership with… Read more »
Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)
xCures to use tumor sequencing information and its platform to pair patients with available treatment options Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence,… Read more »
xCures announces real world biomarker study for patients with FGFR-mutant bladder cancer receiving Balversa®
Tyra Biosciences supported study investigates if non-invasive blood and urine samples provide biomarkers to assess clinical response to erdafitinib treatment Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy. The… Read more »
xCures and BioSpark partner to boost Real World Oncology Data offerings
New partnership allows for a 40,000+ patient dataset to unlock new insights into cancer treatments and outcomes. xCures, Inc. and BioSpark, Inc. are proud to announce their strategic partnership to harmonize and commercialize a joint oncology Real World Data (RWD) offering. The partnership unlocks new insights into the treatment and… Read more »
TARGET: Cancer Podcast to be hosted by media personality Dr. Sanjay Juneja – TheOncDoc
Oncologist and cancer educator Dr. Sanjay Juneja will host xCures’ informative podcast on cancer and technology February 17, 2022 – Oakland, CA. – xCures, a direct-to-patient, and direct-to-physician oncology platform, is proud to announce Sanjay Juneja, MD, as the host to their TARGET: Cancer podcast. Dr. Sanjay Juneja is a leading oncologist… Read more »
xCures Webinar: Implications of new FDA draft guidance on real-world data explained
TORONTO (PRWEB) DECEMBER 01, 2021 The FDA has issued two new draft guidance documents on the use and structure of real-world data in regulatory decision-making. While real-world data has been around for many years, in this webinar the xCures speakers will recap the guidance and discuss what this means for the… Read more »
